BATM Advanced Communications Ltd - Israel-based networking and medical technology company - says it has developed a new test for the rapid and comprehensive diagnosis of tuberculosis. Test takes two hours instead of several days with current methods. Clinical trials to start in second half of this year, fully funded by UN's Stop TB Partnership. Expects sales to begin next year.
Current stock price: 98.40 pence
Year-to-date change: up 5.8%
By Ivan Edwards; ivanedwards@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.


(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately repor...


(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:


(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:


SMALL-CAP WINNERS & LOSERS: De La Rue and BATM shares fall again


BATM to be removed from FTSE indices as nationality assigned to Israel


LONDON MARKET MIDDAY: BoE raises key UK rate to 0.5%; some wanted more


SMALL-CAP WINNERS & LOSERS: BATM ruled Israeli; Braemar sales to rise


(Sharecast News) - Networking and medical laboratory technology company BATM updated the market on the FTSE Nationality Review of Companies published ...


TRADING UPDATES: MJ Hudson and Tandem see results ahead of views


IN BRIEF: BATM Advanced makes first sales of Covid test in Russia


UK shareholder meetings calendar - next 7 days